PCSK9 Forum is made possible thanks to support from AstraZeneca, LIB Therapeutics, Novartis and Sanofi, all of whom have no influence or control of editorial content. More information is available here »

Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

Ulf Landmesser Articles

PlayESC/EAS Task Force issues updated clinical guidance for PCSK9 inhibitors

ESC/EAS Task Force issues updated clinical guidance for PCSK9 inhibitors

This Task Force from the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) has considered new evidence from cardiovascular outcomes studies with evolocumab (FOURIER) and bococizumab (now terminated), new analyses and genetic studies.t Taking account of the cost of these agents, the Task…

read more »
Posted on 25 October 2017 | Posted by Ulf Landmesser | Posted in From the Editors, Videos
How do we identify very high risk patients for PCSK9 inhibition? Part Two

How do we identify very high risk patients for PCSK9 inhibition? Part Two

Reports from the 7th Expert Meeting of PCSK9 Forum The role of imaging: Ulf Landmesser, Charité Universitätsmedizin Berlin, Germany

read more »
Posted on 18 October 2017 | Posted by Ulf Landmesser | Posted in Webcasts, 7th Closed Scientific Expert Meeting of the Editorial Board
The year in cardiology 2015: prevention

The year in cardiology 2015: prevention

PCSK9 Forum Editors, Profs John Chapman, Ulf Landmesser and co-authors discuss the highlights of 2015 in The European Heart Journal.  

read more »
Posted on 20 January 2016 | Posted by John Chapman, Ulf Landmesser | Posted in From the Editors

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.
Educational Partners and Supporters
AstraZeneca

AstraZeneca has provided a grant towards this independent project and has had no involvement in its creation or organisation

LIB Therapeutics

Novartis

Sanofi

© Copyright 2025 PCSK9 Forum. All rights reserved